Measles and rubella monitoring, August 2012
The ECDC measles and rubella monitoring report presents regular updates on measles and rubella transmission in Europe based on reporting from EU and EEA/EFTA countries and ECDC epidemic intelligence activities. This enhanced surveillance report supports efforts by EU Member States and international partners to eliminate measles, rubella and congenital rubella syndrome in EU and the WHO region of Europe by 2015.
ECDC published its latest measles and rubella monitoring report which shows that measles transmission continues to be slow at European level, without any large new outbreaks reported since the previous report. During the 12-month period from July 2011 to June 2012 a total of 10 427 cases were reported of which 90% were notified by France, Italy, Romania, Spain and the United Kingdom.
During the same period, 22 835 rubella cases were reported with Poland and Romania accounting for 99% of the cases. Sweden reported its largest outbreak of rubella since 1996, associated with low vaccination uptake in an anthroposophical community south of Stockholm.
Measles and rubella are targeted for elimination in Europe by 2015. ECDC closely monitors progress towards interruption of endemic transmission through enhanced surveillance of both diseases and epidemic intelligence. Measles and rubella vaccinations are routinely delivered in the form of the measles-mumps-rubella (MMR) vaccine in Europe yet the majority of cases reported were unvaccinated.
Antimicrobial resistance in the EU/EEA (EARS-Net) - Annual Epidemiological Report for 2019
18 Nov 2020 - This report is based on data reported to the European Antimicrobial Resistance Surveillance Network (EARS-Net) for the period 2015 to 2019, retrieved from The European Surveillance System (TESSy) and ECDC’s decentralised data storage for antimicrobial resistance and healthcare-associated infections (ARHAI) on 10 September 2020.
Antimicrobial consumption - Annual Epidemiological Report for 2019
18 Nov 2020 - In 2019, the average total (community and hospital sector combined) consumption of antibacterials for systemic use (Anatomical Therapeutic Chemical (ATC) group J01) in the EU/EEA was 19.4 defined daily doses (DDD) per 1 000 inhabitants per day (country range: 9.5–34.1). During the period 2010–2019, a statistically significant decrease was observed for the EU/EEA overall.
Influenza virus characterisation, October 2020
13 Nov 2020 - This is the first report for the 2020–2021 influenza season. As of week 44/2020, only 39 influenza detections across the WHO European Region had been reported to The European Surveillance System (TESSy); 59% type A viruses, with A(H3N2) prevailing over A(H1N1)pdm09, and 41% type B viruses with none having been ascribed to a lineage. This represents a 97% drop in detections compared with the same period in 2019, probably due to the COVID-19 pandemic and measures introduced to combat it.